154 related articles for article (PubMed ID: 36750990)
1. Transferring measurable residual disease measurement in pediatric acute lymphoblastic leukemia from quantitative real-time PCR to digital droplet PCR.
Luib L; Kreyenberg H; Michaelis S; Handgretinger R; Mezger M
Pediatr Transplant; 2023 Jun; 27(4):e14483. PubMed ID: 36750990
[TBL] [Abstract][Full Text] [Related]
2. A New View on Minimal Residual Disease Quantification in Acute Lymphoblastic Leukemia using Droplet Digital PCR.
Schwinghammer C; Koopmann J; Chitadze G; Karawajew L; Brüggemann M; Eckert C
J Mol Diagn; 2022 Aug; 24(8):856-866. PubMed ID: 35691569
[TBL] [Abstract][Full Text] [Related]
3. Minimal residual disease detection by mutation-specific droplet digital PCR for leukemia/lymphoma.
Shirai R; Osumi T; Keino D; Nakabayashi K; Uchiyama T; Sekiguchi M; Hiwatari M; Yoshida M; Yoshida K; Yamada Y; Tomizawa D; Takae S; Kiyokawa N; Matsumoto K; Yoshioka T; Hata K; Hori T; Suzuki N; Kato M
Int J Hematol; 2023 Jun; 117(6):910-918. PubMed ID: 36867356
[TBL] [Abstract][Full Text] [Related]
4. Droplet Digital PCR Is a Robust Tool for Monitoring Minimal Residual Disease in Adult Philadelphia-Positive Acute Lymphoblastic Leukemia.
Coccaro N; Anelli L; Zagaria A; Casieri P; Tota G; Orsini P; Impera L; Minervini A; Minervini CF; Cumbo C; Parciante E; Carluccio P; Brunetti C; Specchia G; Albano F
J Mol Diagn; 2018 Jul; 20(4):474-482. PubMed ID: 29625246
[TBL] [Abstract][Full Text] [Related]
5. Applicability of droplet digital polymerase chain reaction for minimal residual disease monitoring in Philadelphia-positive acute lymphoblastic leukaemia.
Ansuinelli M; Della Starza I; Lauretti A; Elia L; Siravo V; Messina M; De Novi LA; Taherinasab A; Canichella M; Guarini A; Foà R; Chiaretti S
Hematol Oncol; 2021 Dec; 39(5):680-686. PubMed ID: 34402088
[TBL] [Abstract][Full Text] [Related]
6. Droplet digital PCR for sensitive relapse detection in acute myeloid leukaemia patients transplanted by reduced intensity conditioning.
Gronlund JK; Veigaard C; Juhl-Christensen C; Skou AS; Melsvik D; Ommen HB
Eur J Haematol; 2024 Apr; 112(4):601-610. PubMed ID: 38197567
[TBL] [Abstract][Full Text] [Related]
7. Droplet Digital PCR Is a Reliable Tool for Monitoring Minimal Residual Disease in Acute Promyelocytic Leukemia.
Brunetti C; Anelli L; Zagaria A; Minervini A; Minervini CF; Casieri P; Coccaro N; Cumbo C; Tota G; Impera L; Orsini P; Specchia G; Albano F
J Mol Diagn; 2017 May; 19(3):437-444. PubMed ID: 28268092
[TBL] [Abstract][Full Text] [Related]
8. An update on PCR use for minimal residual disease monitoring in acute lymphoblastic leukemia.
Nunes V; Cazzaniga G; Biondi A
Expert Rev Mol Diagn; 2017 Nov; 17(11):953-963. PubMed ID: 28891364
[TBL] [Abstract][Full Text] [Related]
9. MRD Detection in B-Cell Non-Hodgkin Lymphomas Using Ig Gene Rearrangements and Chromosomal Translocations as Targets for Real-Time Quantitative PCR.
Pott C; Brüggemann M; Ritgen M; van der Velden VHJ; van Dongen JJM; Kneba M
Methods Mol Biol; 2019; 1956():199-228. PubMed ID: 30779036
[TBL] [Abstract][Full Text] [Related]
10. Comparative analysis between RQ-PCR and digital-droplet-PCR of immunoglobulin/T-cell receptor gene rearrangements to monitor minimal residual disease in acute lymphoblastic leukaemia.
Della Starza I; Nunes V; Cavalli M; De Novi LA; Ilari C; Apicella V; Vitale A; Testi AM; Del Giudice I; Chiaretti S; Foà R; Guarini A
Br J Haematol; 2016 Aug; 174(4):541-9. PubMed ID: 27172403
[TBL] [Abstract][Full Text] [Related]
11. Research Topic: Measurable Residual Disease in Hematologic Malignancies. Can digital droplet PCR improve measurable residual disease monitoring in chronic lymphoid malignancies?
Assanto GM; Del Giudice I; Della Starza I; Soscia R; Cavalli M; Cola M; Bellomarino V; Di Trani M; Guarini A; Foà R
Front Oncol; 2023; 13():1152467. PubMed ID: 36998457
[TBL] [Abstract][Full Text] [Related]
12. Digital PCR for Minimal Residual Disease Quantitation Using Immunoglobulin/T-Cell Receptor Gene Rearrangements in Acute Lymphoblastic Leukemia: A Proposed Analytic Algorithm.
Lu Y; Li Z; Lim EH; Huan PT; Kham SKY; Yeoh AE
J Mol Diagn; 2022 Jun; 24(6):655-665. PubMed ID: 35390515
[TBL] [Abstract][Full Text] [Related]
13. Droplet Digital PCR Improves IG-/TR-based MRD Risk Definition in Childhood B-cell Precursor Acute Lymphoblastic Leukemia.
Della Starza I; Nunes V; Lovisa F; Silvestri D; Cavalli M; Garofalo A; Campeggio M; De Novi LA; Soscia R; Oggioni C; Mussolin L; Biondi A; Guarini A; Valsecchi MG; Conter V; Biffi A; Basso G; Foà R; Cazzaniga G
Hemasphere; 2021 Mar; 5(3):e543. PubMed ID: 33655199
[TBL] [Abstract][Full Text] [Related]
14. Utilizing the prognostic impact of minimal residual disease in treatment decisions for pediatric acute lymphoblastic leukemia.
Ceppi F; Rizzati F; Colombini A; Conter V; Cazzaniga G
Expert Rev Hematol; 2021 Sep; 14(9):795-807. PubMed ID: 34374613
[TBL] [Abstract][Full Text] [Related]
15. One-Step Multiplexed Droplet Digital Polymerase Chain Reaction for Quantification of p190 BCR-ABL1 Fusion Transcript in B-Lymphoblastic Leukemia.
Martinez RJ; Kang Q; Nennig D; Bailey NG; Brown NA; Betz BL; Tewari M; Thyagarajan B; Bachanova V; Mroz P
Arch Pathol Lab Med; 2022 Jan; 146(1):92-100. PubMed ID: 33769465
[TBL] [Abstract][Full Text] [Related]
16. Real-time quantitative PCR for the detection of minimal residual disease in acute lymphoblastic leukemia using junctional region specific TaqMan probes.
Pongers-Willemse MJ; Verhagen OJ; Tibbe GJ; Wijkhuijs AJ; de Haas V; Roovers E; van der Schoot CE; van Dongen JJ
Leukemia; 1998 Dec; 12(12):2006-14. PubMed ID: 9844931
[TBL] [Abstract][Full Text] [Related]
17. Digital Droplet PCR Is a Reliable Tool to Improve Minimal Residual Disease Stratification in Adult Philadelphia-Negative Acute Lymphoblastic Leukemia.
Della Starza I; De Novi LA; Santoro A; Salemi D; Spinelli O; Tosi M; Soscia R; Paoloni F; Cappelli LV; Cavalli M; Apicella V; Bellomarino V; Di Lello E; Vitale A; Vignetti M; Fabbiano F; Rambaldi A; Bassan R; Guarini A; Chiaretti S; Foà R
J Mol Diagn; 2022 Aug; 24(8):893-900. PubMed ID: 35710027
[TBL] [Abstract][Full Text] [Related]
18. Comparison of RNA- and DNA-based methods for measurable residual disease analysis in NPM1-mutated acute myeloid leukemia.
Pettersson L; Johansson Alm S; Almstedt A; Chen Y; Orrsjö G; Shah-Barkhordar G; Zhou L; Kotarsky H; Vidovic K; Asp J; Lazarevic V; Saal LH; Fogelstrand L; Ehinger M
Int J Lab Hematol; 2021 Aug; 43(4):664-674. PubMed ID: 34053184
[TBL] [Abstract][Full Text] [Related]
19. Minimal Residual Disease Detection by Droplet Digital PCR in Multiple Myeloma, Mantle Cell Lymphoma, and Follicular Lymphoma: A Comparison with Real-Time PCR.
Drandi D; Kubiczkova-Besse L; Ferrero S; Dani N; Passera R; Mantoan B; Gambella M; Monitillo L; Saraci E; Ghione P; Genuardi E; Barbero D; Omedè P; Barberio D; Hajek R; Vitolo U; Palumbo A; Cortelazzo S; Boccadoro M; Inghirami G; Ladetto M
J Mol Diagn; 2015 Nov; 17(6):652-60. PubMed ID: 26319783
[TBL] [Abstract][Full Text] [Related]
20. Minimal residual disease (MRD) detection using rearrangement of immunoglobulin/T cell receptor genes in adult patients with acute lymphoblastic leukemia (ALL).
Shahkarami S; Mehrasa R; Younesian S; Yaghmaie M; Chahardouli B; Vaezi M; Rezaei N; Nikbakht M; Alimoghaddam K; Ghavamzadeh A; Tavakkoly-Bazzaz J; Ghaffari SH
Ann Hematol; 2018 Apr; 97(4):585-595. PubMed ID: 29392424
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
